Hengrui Pharma, founded in 1970, is an international pharmaceutical enterprise engaged in the research and promotion of innovative and high-quality drugs, focusing on anti-tumor, surgical drugs, autoimmune diseases, metabolic diseases, cardiovascular diseases and other fields. In the "Annual Analysis of Pharmaceutical R&D Trends in 2022" published by InformaPharmaIntelligence, a global medical think tank information platform, Hengrui Pharma ranked 16, setting a new high for China pharmaceutical companies in this list; In the list of the top 50 global pharmaceutical companies in 2022 published by Pharmaceutical Manager magazine in the United States, Hengrui has been on the list for four consecutive years, and its ranking has increased year by year, setting a new high of ranking 32nd, refreshing the best performance of China pharmaceutical companies in the list; The company has been selected as one of the top 100 pharmaceutical enterprises in China for many years, and in 2022, it was ranked as the best industrial enterprise in China pharmaceutical R&D product line again.
For more than 50 years, Hengrui Pharma has always been rooted in China, facing the world, focusing on health undertakings, focusing on frontier fields, overcoming difficulties and promoting the high-quality development of the pharmaceutical industry. The company regards scientific and technological innovation as the first development strategy, and continues to invest heavily in research and development. In the past ten years, the company has invested 23.8 billion yuan in R&D, of which 202 1 invested 6.203 billion yuan, accounting for 23.95% of the operating income, ranking first in the industry. The company has set up R&D centers or branches in Lianyungang, Shanghai, Chengdu, the United States, Europe and other places, and has built a large-scale, professional and all-round global R&D team with more than 5,000 people. At present, the company has approved the listing of 12 innovative drugs such as Rivetamide, Herzobupa and Karelizumab, and the new drug 1 introduced by the company has also been approved for listing, which is the first innovative drug approved for listing among the company's foreign cooperation products. More than 60 innovative drugs are under clinical development, and more than 260 clinical trials have been carried out at home and abroad. The company has rich R&D channels, and besides the traditional advantageous tumor field, it also foresees a wide range of therapeutic fields such as autoimmune diseases, pain management, cardiovascular diseases and metabolic diseases. The company has also established a number of internationally leading new technology platforms with independent intellectual property rights, which provide a strong foundation for innovation and research and development. By the end of 2022, the company had applied for 2,064 invention patents, 583 PCT patents, 507 domestic valid invention patents and 6 18 foreign patents granted by Europe, America and Japan.
The company continues to steadily promote internationalization. By the end of 20021,Hengrui Pharma's products have entered more than 40 countries, and continue to accelerate the development of the global market, focusing on emerging markets. The company adheres to both independent research and development and open cooperation, and strengthens international cooperation on the basis of endogenous development. Through cooperation with American and Korean companies, the company authorized innovative drugs with independent intellectual property rights, such as SHR2554, Karelizumab and SHR0302. In addition, Hengrui Pharma has obtained more than 20 registration documents in Europe, America and Japan, including injections, oral preparations and inhaled anesthetics, which has improved the drug accessibility of patients in different parts of the world.